Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Motohiro Tamiya

Showing results (91-100 of 192) with videos related to

Pageof 20
Sort By:
Science Translational Medicine|February 12, 2025
Coactivation of innate immune suppressive cells induces acquired resistance against combined TLR agonism and PD-1 blockadeHitomi Nishinakamura, Sayoko Shinya, Takuma Irie, et al.
Immunotherapy|May 25, 2021
Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcomaHayato Kawachi, Kei Kunimasa, Yoji Kukita, et al.
European Journal of Hospital Pharmacy : Science and Practice|January 9, 2018
Mandatory dexamethasone strictly monitored by pharmacists reduces the severity of pemetrexed-induced skin rashNaoko Usui, Yoko Kondo, Noriko Ryota, et al.
Investigational New Drugs|November 5, 2017
Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutationsMotohiro Tamiya, Akihiro Tamiya, Takayuki Shiroyama, et al.
BMC Cancer|February 5, 2020
Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumabMitsunori Morita, Motohiro Tamiya, Daichi Fujimoto, et al.
Cancer Medicine|March 11, 2022
Comparison of sampling methods for next generation sequencing for patients with lung cancerKei Kunimasa, Shingo Matsumoto, Kazumi Nishino, et al.
Cancer Genetics|April 26, 2021
Late recurrence of lung adenocarcinoma harboring EGFR exon 20 insertion (A763_Y764insFQEA) mutation successfully treated with osimertinibKei Kunimasa, Kazumi Nishino, Yoji Kukita, et al.
JACC. Cardiooncology|August 16, 2021
Cardiac Adverse Events in <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer Treated With OsimertinibKei Kunimasa, Risa Kamada, Toru Oka, et al.
Anticancer Research|September 6, 2017
Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung CancerAkihiro Tamiya, Motohiro Tamiya, Kenji Nakahama, et al.
Cancer|September 8, 2018
Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study)Akito Hata, Nobuyuki Katakami, Reiko Kaji, et al.
Pageof 20

Showing results (91-100 of 192) with videos related to

Sort By:
Pageof 20
Science Translational Medicine|February 12, 2025
Coactivation of innate immune suppressive cells induces acquired resistance against combined TLR agonism and PD-1 blockadeHitomi Nishinakamura, Sayoko Shinya, Takuma Irie, et al.
Immunotherapy|May 25, 2021
Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcomaHayato Kawachi, Kei Kunimasa, Yoji Kukita, et al.
European Journal of Hospital Pharmacy : Science and Practice|January 9, 2018
Mandatory dexamethasone strictly monitored by pharmacists reduces the severity of pemetrexed-induced skin rashNaoko Usui, Yoko Kondo, Noriko Ryota, et al.
Investigational New Drugs|November 5, 2017
Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutationsMotohiro Tamiya, Akihiro Tamiya, Takayuki Shiroyama, et al.
BMC Cancer|February 5, 2020
Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumabMitsunori Morita, Motohiro Tamiya, Daichi Fujimoto, et al.
Cancer Medicine|March 11, 2022
Comparison of sampling methods for next generation sequencing for patients with lung cancerKei Kunimasa, Shingo Matsumoto, Kazumi Nishino, et al.
Cancer Genetics|April 26, 2021
Late recurrence of lung adenocarcinoma harboring EGFR exon 20 insertion (A763_Y764insFQEA) mutation successfully treated with osimertinibKei Kunimasa, Kazumi Nishino, Yoji Kukita, et al.
JACC. Cardiooncology|August 16, 2021
Cardiac Adverse Events in <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer Treated With OsimertinibKei Kunimasa, Risa Kamada, Toru Oka, et al.
Anticancer Research|September 6, 2017
Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung CancerAkihiro Tamiya, Motohiro Tamiya, Kenji Nakahama, et al.
Cancer|September 8, 2018
Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study)Akito Hata, Nobuyuki Katakami, Reiko Kaji, et al.
Pageof 20